metabasis


Also found in: Dictionary.

metabasis

 [mĕ-tab´ah-sis]
change in the manifestations or course of a disease.

me·tab·a·sis

(mĕ-tab'ă-sis),
Rarely used term for a change of any kind in symptoms or course of a disease.
[G. a passing over, change, fr. metabainō, to pass over]

metabasis

/me·tab·a·sis/ (mĕ-tab´ah-sis) a change in the manifestations or course of a disease.

metabasis

An obsolete, nonspecific term for any alteration in the natural course of a disease process.

me·tab·a·sis

(mĕ-tab'ă-sis)
Rarely used termfor a change of any kind in symptoms or course of a disease.
[G. a passing over, change, fr. metabainō, to pass over]

metabasis

change in the manifestations or course of a disease.
Mentioned in ?
References in periodicals archive ?
The conference call will be webcast live on the Metabasis website at http://www.
Metabasis says the HepDirect technology is a prodrug technology that specifically targets production of the biologically active form of certain drugs to the liver and preclinical studies have show that the use of the technology may result in higher active drug concentrations in the liver and decreased exposure to non-liver tissue.
The acquisition of Metabasis builds on our strategy to cultivate a robust pipeline with a broad array of royalty bearing assets and early stage pipeline programs.
Under the transaction, Metabasis stockholders will receive a cash payment at the closing of the transaction of approximately $3.
This methodology has been used by Metabasis in its drug discovery programs for type 2 diabetes.
MB07803 is a second generation compound that Metabasis internally discovered that inhibits the gluconeogenesis pathway.
2006 highlights: Metabasis made substantial progress on all five of its clinical programs
As of June 30, 2009, Metabasis had cash and cash equivalents totaling $6.
SAN DIEGO, March 6 /PRNewswire-FirstCall/ -- Metabasis Therapeutics , announced today that John Beck, senior vice president of finance and chief financial officer of Metabasis will present at Cowen and Company's 27th Annual Health Care Conference at the Boston Marriott Copley Place in Boston.
Metabasis and Merck entered into a collaboration and license agreement in June 2005 focused on the discovery, development and commercialization of AMPK activators for the treatment of various metabolic diseases.
Metabasis and Roche entered into a collaboration and license agreement in August 2008 which included a $10 million upfront payment and provided for additional payments upon achievement of predetermined preclinical and clinical development events, as well as regulatory and commercialization events for each product, and royalties on net sales of products from the collaboration.